Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New monthly shot could simplify diabetes care

NCT ID NCT07563699

First seen May 19, 2026 · Last updated May 25, 2026 · Updated 1 time

Summary

This study tests a new long-acting version of semaglutide (a diabetes drug) that is given once a month instead of weekly. It aims to see if it is safe and works well for controlling blood sugar and weight in 24 adults with type 2 diabetes. Participants must already be on weekly semaglutide and have stable blood sugar levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mapi pharma Investigational Site ISR001

    Tel Aviv, 6423906, Israel

Conditions

Explore the condition pages connected to this study.